Interviews

The University Hospitals CINEMA program aims to address issues and narrow gaps in obesity management, with a focus on meeting patients where they are and providing them tools for success, says Ian Neeland, MD.

Robert Lustig, MD, MSL, explains how the US health care industry needs to shift from measuring body mass index and obesity to measuring cardiometabolic health, which affects 93% of Americans, including children.

Experts share their biggest takeaways from the European Hematology Association (EHA) 2024 Congress.

Suzanne Lentzsch, MD, PhD, of Columbia University, presented promising results of linvoseltamab for treating relapsed/refractory multiple myeloma (RRMM) at the European Hematology Association 2024 Congress.

"As a health care provider and as a psychiatrist, it's something that I think about first—instead of step therapy, when I have a patient with postpartum depression, this is what they need to be on," Rachel Dalthorp, MD, explains.

In part 3 of an interview, MD Anderson’s Ravin Ratan, MD, MEd, discusses neoadjuvant immune checkpoint blockade for 2 specific types of soft tissue sarcomas.

Patients with diabetes who have private insurance are more likely to be prescribed a continuous glucose monitor (CGM) compared with those with government insurance, says Chase Hendrickson, MD, MPH, Vanderbilt University Medical Center.

For the third episode in our special Pride Month series, we speak with Patrick McGovern, CEO of Callen-Lorde since August of 2023 and an outspoken advocate for HIV; lesbian, gay, bisexual, transgender, queer, plus (LGBTQ+); and community health.

Ana Lacerda, MD, MSc, of the Portuguese Institute of Oncology, advocates for early palliative care integration in pediatric patients with hematologic diseases.

Mohamad Mohty, MD, PhD, of Saint-Antoine Hospital and Sorbonne University, highlights how immunotherapies are offering various effective treatment options for patients with multiple myeloma and improving quality of life for relapsed/refractory patients.

Joseph Mikhael, MD, MEd, FRCPC, FACP, of the International Myeloma Foundation, HonorHealth, and TGen, notes that US physicians have more flexibility when treating patients with early relapsed/refractory multiple myeloma, whereas those in Europe must follow stricter protocols.

It’s important for clinicians to listen to patients and know how heart disease may affect women differently than men, said Kathryn Lindley, MD, FACC, Vanderbilt University Medical Center.

Jennifer Vidrine, MBBS, MRCP, of Newcastle upon Tyne Hospitals, stresses the importance of providing personalized, beneficial end-of-life care for patients with hematologic diseases.

Ryan Jacobs, MD, of Atrium Health Levine Cancer Institute, explains that the phase 2 CAPTIVATE study's fixed-duration treatment cohort shows long-term progression-free survival for patients with chronic lymphocytic leukemia (CLL) who received the first-line treatment of ibrutinib and venetoclax.

This investigation used data from The US Oncology Network on trends in lung cancer stage when patients present for care.

Catherine Diefenbach, MD, an American Society of Hematology expert and director of the Clinical Lymphoma Program at NYU Langone's Perlmutter Cancer Center, discussed the evolving state of diffuse large B-cell lymphoma (DLBCL) therapeutics and exciting areas of research.

Michael Thorpy, MD, professor of neurology, Albert Einstein College of Medicine, explored the mechanism of action in orexin agonists, which has been indicated for idiopathic hypersomnia.

Brian Koffman, MDCM, DCFP, FCFP, DABFP, MSEd, of CLL Society, details the comprehensive multidisciplinary support for patients with chronic lymphocytic leukemia (CLL) at the European Hematology Association (EHA) 2024 Congress.

Marta Rodríguez Martínez, PhD, sustainability officer of the European Molecular Biology Laboratory, highlights the primary sources of scientific research waste and how to reduce them.

Chesahna Kindred, MD, MBA, FAAD, board-certified dermatologist, Kindred Hair & Skin Center, discusses how diversity in clinical trials are helping bridge the racial health equity gap in psoriasis care.

Kheir Mugwaneza, the lead project manager of the Immigrant and Refugee Health Program at Allegheny Health Network, discusses how the program is working to address gaps in care for this community.

Ali Khawar, principal deputy assistant secretary with the Employee Benefits Security Administration (EBSA), US Department of Labor, explains how the Mental Health Parity and Addiction Equity Act (MHPAEA) aims to address the mental health crisis in the US.

John Hood, PhD, cofounder and CEO of Endeavor BioMedicines, explains the potential advantages of ENV-101 during a time with very few treatments for idiopathic pulmonary fibrosis (IPF).

On this episode of Managed Care Cast, an expert from the University of Minnesota discusses the lack of consideration academic medical centers have for equity when developing governance for AI technologies.

Migvis Monduy, MD, medical director of Neuromuscular and Movement Disorders Programs at Nicklaus Children's Hospital, discussed challenges in Duchenne muscular dystrophy (DMD) treatment access and how policy changes may support patients with DMD.

Jeff Levin-Scherz, MD, MBA, population health leader at WTW, explains that obesity care in the US is inconsistent and costly, with significant gaps across Medicare, Medicaid, and employer-based insurance.

Emily Touloukian, DO, medical oncologist, practice president, and managing partner at Coastal Cancer Center, discusses the importance of patient advocacy when it comes to current issues such as drug shortages and mail order restrictions.

Continuing with our Pride Month podcast series, in this episode we speak with Perry Halkitis, PhD, MS, MPH, dean of the Rutgers School of Public Health, and James F. Dougherty, VMD, MS, current member of Rutgers' Board of Governors.

Experts share what they are looking forward to most at this year's European Hematology Association (EHA) Congress.

Amit Singal, MD, medical director of the Liver Tumor Program at UT Southwestern Medical Center, discussed the current outlook for patients with hepatocellular carcinoma (HCC) and how to choose between therapies.